5-Hydroxyindoleacetic acid
|
Basic information |
| Metabolite name | 5-Hydroxyindoleacetic acid |
 | HMDB0000763 |
 |
C05635 |
 |
1826 |
| Synonyms | 5-hydroxyindole-3-acetic acid; |
| No. of studies | 65 |
|
Basic information |
| Metabolite name | 5-Hydroxyindoleacetic acid |
| HMDB0000763 |
|
C05635 |
|
1826 |
| Synonyms | 5-hydroxyindole-3-acetic acid; |
| No. of studies | 65 |
|
Relationship between 5-Hydroxyindoleacetic acid and depression (count: 65) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M023 | Type2 | CUMS + high dose of venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M023 | Type2 | CUMS + middle dose of venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M023 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M037 | Type2 | sertraline treatment group one-week vs. baseline | Serum | Human | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Up |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1010 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1033 | Type1 | small intestinal bacterial overgrowth and chronic diarrhea group vs. control group | Urine | Human | Up |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic constipation group, after rifaximin treatment vs. baseline | Urine | Human | Up |
| Study M1033 | Type2 | small intestinal bacterial overgrowth and chronic diarrhea group, after rifaximin treatment vs. baseline | Urine | Human | Down |
| Study M1034 | Type1 | small intestinal bacterial overgrowth and chronic diarrhea group vs. control group | Urine | Human | Up |
| Study M1035 | Type2 | mood disorder group, after tryptophan-rich diet vs. baseline | Urine | Human | Up |
| Study M1036 | Type1 | IBS-D group vs. control group | Urine | Human | Up |
| Study M1036 | Type2 | IBS-D with low-tryptophan and FODMAP diet subgroup, after diet intervention vs. baseline | Urine | Human | Down |
| Study M1040 | Type2 | CUMS + Roseburia inulinivorans group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Striatum | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Hypothalamus | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Serum | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Colon | Wistar rat | Down |
| Study M1059 | Type1 | CRS group vs. control group | Cortex | Wistar rat | Down |
| Study M1063 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M1106 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1106 | Type2 | CUMS + high dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type2 | CUMS + middle dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1107 | Type2 | CRS + FMT of healthy controls group vs. CRS group | Serum | C57/6 J mouse | Up |
| Study M1108 | Type1 | CRS group vs. control group | Serum | C57/6 J mouse | Down |
| Study M1108 | Type3 | Roseburia Intestinalis. group vs. CRS group | Serum | C57/6 J mouse | Down |
| Study M1118 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M1118 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1118 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1118 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | C57BL/6 mouse | Up |
| Study M1134 | Type1 | prenatal stress group vs. control group, female offspring | Brainstem | Swiss mouse | Up |
| Study M1138 | Type1 | unpredictable subchronic stress group vs. control group | Hippocampus | Swiss mouse | Up |
| Study M1138 | Type2 | unpredictable subchronic stress + imipramine group vs. unpredictable subchronic stress group | Hippocampus | Swiss mouse | Down |
| Study M126 | Type1 | LPS group vs. control group | Brain | CD-1 mouse | Up |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD acute vortioxetine group vs. SD acute control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. FSL sustained control group | Plasma | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Midbrain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Striatum | Sprague-Dawley rat | Down |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Down |
| Study M170 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M170 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M171 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M480 | Type2 | CGA-treated group vs. sleep deprivation group | Urine | Wistar rat | Down |
| Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M525 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M558 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + high dose of volatile oils group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M559 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + low dose of volatile oils group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + low dose of polysaccharides group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M563 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M563 | Type2 | CUMS + TCM group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M570 | Type1 | CMS group vs. control group | Serum | BALB/c mouse | Down |
| Study M574 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Hippocampus | Sprague-Dawley rat | Up |
| Study M574 | Type2 | CMS + n-3 PUFA supplementary group vs. CMS + normal diet group | Hippocampus | Sprague-Dawley rat | Down |
| Study M579 | Type1 | postpartum depression group vs. control group | Urine | Human | Up |
| Study M627 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + high dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M665 | Type1 | CRS group vs. control group | Hypothalamus | C57BL/6 mouse | Down |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M672 | Type2 | SMG + Hemerocallis citrina extracts group vs. SMG group | Urine | Sprague-Dawley rat | Up |
| Study M705 | Type1 | maternal separation group vs. control group | Striatum | C57BL/6 mouse | Down |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Up |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Up |
| Study M724 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M728 | Type1 | CRS group vs. control group | Hippocampus | C57BL/6 J mouse | Down |
| Study M766 | Type1 | CUS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M787 | Type1 | CRS group vs. control group | Colon | Wistar rat | Down |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Down |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Down |
| Study M835 | Type1 | CRS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M848 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M848 | Type2 | CRS + dexamethasone group vs. CRS group | Serum | C57BL/6 J mouse | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M882 | Type1 | CUMS group vs. control group | Jejunum | Sprague-Dawley rat | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M942 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Serum | C57BL/6 mouse | Up |
| Study M951 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M951 | Type2 | CUMS + paeoniflorin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M953 | Type2 | CRS + Shugan Granule group vs. CRS group | Faece | Sprague-Dawley rat | Down |
| Study M969 | Type1 | CUMS group vs. control group | Hippocampus | ICR mouse | Up |
| Study M969 | Type2 | CUMS + Changyu Daotan Decoction group vs. CUMS group | Hippocampus | ICR mouse | Down |
| Study M978 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M978 | Type2 | CUMS + low dose of Rehmanniae Radix group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M978 | Type2 | CUMS + high dose of Rehmanniae Radix group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M978 | Type2 | CUMS + fluoxetine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M982 | Type1 | adult MDD group vs. adult control group | Plasma | Human | Up |
| Study M982 | Type2 | adult MDD group, post-treatment vs. baseline | Plasma | Human | Down |